GL1X · GenesisL1 explorer

Research workbench

Crystal structure of macrolide 2'-phosphotransferase MphH from Brachybacterium faecium in complex with azithromycin

Analyse Crystal structure of macrolide 2'-phosphotransferase MphH from Brachybacterium… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
5UXD
Type
protein
Length
599 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v2 / PDB Bank
Contract
0xd58B01f6C18086e5202cdC5D7Ad3E41790360102
Owner
0xF4e1AA6f26B7DA48EeAD9B24a97927303eeA07b8
Resolution
1.7
Source
Brachybacterium faecium (strain ATCC 43885 / DSM 4810 / NCIB 9860)
Molecule
Macrolide 2'-phosphotransferase MphH
UniProt
C7MEP1
Ligands
ZIT, CL, SO4
Pockets
4 · best druggability 0.76

Structure

x-ray diffraction · resolution 1.7 · 2 distinct chains · 48% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMacrolide 2'-phosphotransferase MphHprotein30047% helix, 19% strandC7MEP1
BMacrolide 2'-phosphotransferase MphHprotein29948% helix, 17% strandC7MEP1

Ligands and binding sites

  • ZIT · Azithromycin · ligand · 3 copies · chains A, B
  • CL · Chloride ion · ion · 6 copies · chains A, B
  • SO4 · Sulfate ion · ion · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

4 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110720.760.7866ZIT, CL
24670.620.7634CL
33480.600.7740empty
43710.600.7636CL

Interfaces

1 interface between chains.

  • A–B · 665 Ų buried · 8 hydrogen bonds · protein-protein

Compared structures

  • 5UXD · Crystal structure of macrolide 2'-phosphotransferase mphh from brachybacterium faecium in… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.